Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.
Jorge E. Cortes, MD, director, Georgia Cancer Center, Augusta University, explains how ruxolitinib (Jakafi) is used to treat various myeloproliferative neoplasms and which patients require other therapies.
Ruxolitinib is very effective in myelofibrosis, particularly for patients who have a large spleen size or are symptomatic. Since ruxolitinib does not cure the disease, patients without these issues do not have the same benefit.
Ruxolitinib is also approved for the treatment of polycythemia vera and essential thrombocythemia for patients who have not responded to initial therapy and for whom few options are available.
<< View more from the 24th Annual International Congress on Hematologic Malignancies
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More